Dulaglutide

Plain-language summary

A once-weekly injectable GLP-1 receptor agonist FDA-approved for type 2 diabetes and to reduce cardiovascular events in adults with diabetes.

Regulatory status

Evidence snapshot

Established. Supported by multiple well-conducted randomized trials and/or systematic reviews with consistent results.

How it works

Mimics GLP-1 to boost glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.

Approved uses and researched uses

Researched uses are studied but not FDA-approved and may be off-label. This is not a recommendation to use them.

Known risks and uncertainties

Common effects are nausea, diarrhea, vomiting, and abdominal pain. Serious potential risks include pancreatitis, gallbladder disease, and hypoglycemia when combined with insulin or sulfonylureas. The label carries a boxed warning for thyroid C-cell tumors from rodent studies.

Cautions and contraindications

Contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and in those with serious hypersensitivity to dulaglutide.

Consumer considerations

• Approved primarily for diabetes and cardiovascular risk, not marketed as a weight-loss drug.
• Weight reduction is usually smaller than with semaglutide or tirzepatide.
• Delivered in a once-weekly pre-filled pen.
• GI side effects are common early and often ease over time.
• It is not the same as compounded GLP-1 products.

Questions to ask a licensed clinician

• Is dulaglutide the best GLP-1 option for my diabetes and heart-risk profile?
• How does its weight effect compare with other GLP-1 drugs if that matters to me?
• How do I manage early GI side effects?
• Do I have thyroid or pancreatic risks that are contraindications?
• How will we monitor blood sugar and kidney function?

Sources